title: Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model.
abstract: Introduction. We examined the murine hepatectomy model of liver regeneration (LR) in the setting of neoadjuvant chemotherapy. Methods. C57BL/6 mice were randomized to receive neoadjuvant intraperitoneal (IP) injections of a control, oxaliplatin (15 mg/kg), or irinotecan (100 mg/Kg or 250 mg/Kg) solution. Hepatectomy (70%) was performed 14 days after the final IP treatment. Animals were sacrificed at postoperative day (D) 0, 1, 2, 3, and 7. Liver remnants and serum were collected for analysis. T-tests for independent samples were used for statistical comparisons. Results. For oxaliplatin, percent LR did not differ at D1 or D2 but was significantly less at D3 (89.0% versus 70.0%, P = 0.048) with no difference on D7 (P = 0.21). Irinotecan-treated mice at both dose levels (100 mg/Kg and 250 mg/Kg) showed no significant differences in LR. BrdU incorporation was significantly decreased in oxaliplatin-treated animals (D1,2,3). Conclusions. Neoadjuvant oxaliplatin but not irinotecan impairs early LR in a posthepatectomy murine model which correlates with decreased DNA synthesis.
authors.affiliation: Liver Tumor Program, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA.
authors.forename: Perry A
authors.initials: PA
authors.lastname: Soriano
authors.forename: Nian
authors.initials: N
authors.lastname: Liu
authors.forename: Erick
authors.initials: E
authors.lastname: Castillo
authors.forename: Brock
authors.initials: B
authors.lastname: Foster
authors.forename: Avo
authors.initials: A
authors.lastname: Artinyan
authors.forename: Joseph
authors.initials: J
authors.lastname: Kim
authors.forename: Wendong
authors.initials: W
authors.lastname: Huang
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Wagman